Arbutus biopharma and antios therapeutics announce clinical collaboration agreement to evaluate ab-729 in combination with ati-2173 in subjects with chronic hepatitis b virus infection

Mendham, n.j. and warminster, pa., june 29, 2021 (globe newswire) -- antios therapeutics, inc. and arbutus biopharma corporation (nasdaq: abus) today announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination of arbutus' proprietary galnac delivered rnai therapeutic, ab-729, antios' proprietary active site polymerase inhibitor nucleotide (aspin), ati-2173, and viread (tenofovir disoproxil fumarate), for the treatment of subjects with chronic hepatitis b virus (hbv) infection.
ABUS Ratings Summary
ABUS Quant Ranking